Completed PHASE2 INTERVENTIONAL 3-arm NCT03322137

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris

Sponsor: Sienna Biopharmaceuticals

Conditions Pruritus Psoriasis Vulgaris

Interventions SNA-120 Vehicle

Updated 11 times since 2017 Last updated: Feb 4, 2019 Started: Oct 10, 2017 Primary completion: Sep 10, 2018 Completion: Oct 22, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pruritus and Psoriasis Vulgaris and is currently completed. Sienna Biopharmaceuticals leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Mar 2019 — Jan 2021 [monthly]

Completed PHASE2
Dec 2018 — Mar 2019 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jul 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Nov 2017 — May 2018 [monthly]

Recruiting PHASE2

First recorded

Oct 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sienna Biopharmaceuticals

Data source: Sienna Labs

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Austin, United States , Clarkston, United States , Dallas, United States , Denver, United States , Doral, United States , East Windsor, United States , Farmington, United States , Fort Smith, United States , Fountain Valley, United States and 28 more locations